Baker Bros. Advisors LP has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $9.34 Billion distributed in 93 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Bei Gene, Ltd. with a value of $2.37B, Incyte Corp with a value of $2.03B, Acadia Pharmaceuticals Inc with a value of $660M, Summit Therapeutics Inc. with a value of $535M, and Madrigal Pharmaceuticals, Inc. with a value of $419M.

Examining the 13F form we can see an increase of $1.81B in the current position value, from $7.52B to 9.34B.

Baker Bros. Advisors LP is based out at New York, NY

Below you can find more details about Baker Bros. Advisors LP portfolio as well as his latest detailed transactions.

Portfolio value $9.34 Billion
Healthcare: $9.33 Billion

Stock Holdings Table Market Cap. of $300 Millions to $2 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 93
  • Current Value $9.34 Billion
  • Prior Value $7.52 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 6 stocks
  • Additional Purchases 16 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 2 stocks
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.